What is Plant Bioscience?
Plant Bioscience is a biotechnology firm dedicated to revolutionizing the treatment of serious infections. The company focuses on developing innovative oligonucleotide-based antimicrobials to combat the growing threat of antimicrobial resistance (AMR). Their research aims to create novel medicines effective against resistant bacterial strains, thereby improving patient well-being and addressing a critical global healthcare challenge. The company's work places it at the forefront of drug discovery and development within the specialized biotech sector.
How much funding has Plant Bioscience raised?
Plant Bioscience has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2019): $1.2M with participation from REPAIR Impact Fund
Key Investors in Plant Bioscience
REPAIR Impact Fund
The REPAIR Impact Fund, backed by Novo Holdings, is dedicated to revitalizing the anti-infective pipeline to combat antimicrobial resistance. It strategically invests in early-stage companies developing therapies against resistant microorganisms, addressing a critical global health crisis.
What's next for Plant Bioscience?
The recent major strategic investment indicates Plant Bioscience is poised for significant scaling and further research and development. This capital infusion is expected to accelerate the advancement of their antimicrobial pipeline, potentially leading to clinical trials and eventual market entry. The company's focus on AMR positions it to address a pressing global health need, attracting further strategic partnerships and financing as it progresses through its development lifecycle.
See full Plant Bioscience company page
